BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 29573765)

  • 1. Risk Factors for the Development of Postembolization Syndrome after Transarterial Chemoembolization for Hepatocellular Carcinoma Treatment.
    Lima M; Dutra S; Gomes FV; Bilhim T; Coimbra É
    Acta Med Port; 2018 Jan; 31(1):22-29. PubMed ID: 29573765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Predictive Model for Postembolization Syndrome after Transarterial Hepatic Chemoembolization of Hepatocellular Carcinoma.
    Khalaf MH; Sundaram V; AbdelRazek Mohammed MA; Shah R; Khosla A; Jackson K; Desai M; Kothary N
    Radiology; 2019 Jan; 290(1):254-261. PubMed ID: 30299233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transarterial hepatic chemoembolization with 70-150 µm drug-eluting beads: assessment of clinical safety and liver toxicity profile.
    Odisio BC; Ashton A; Yan Y; Wei W; Kaseb A; Wallace MJ; Vauthey JN; Gupta S; Tam AL
    J Vasc Interv Radiol; 2015 Jul; 26(7):965-71. PubMed ID: 25979305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prediction model for liver abscess developing after transarterial chemoembolization in patients with hepatocellular carcinoma.
    Shin JU; Kim KM; Shin SW; Min SY; Park SU; Sinn DH; Gwak GY; Choi MS; Lee JH; Paik SW; Yoo BC; Koh KC
    Dig Liver Dis; 2014 Sep; 46(9):813-7. PubMed ID: 24881853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Single-Center Retrospective Comparison of Doxorubicin-Loaded HepaSphere Transarterial Chemoembolization with Conventional Transarterial Chemoembolization for Patients with Unresectable Hepatocellular Carcinoma.
    Kucukay F; Badem S; Karan A; Ozdemir M; Okten RS; Ozbulbul NI; Kucukay MB; Unlu I; Bostanci EB; Akdogan M
    J Vasc Interv Radiol; 2015 Nov; 26(11):1622-9. PubMed ID: 26321015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dexamethasone Prophylaxis to Alleviate Postembolization Syndrome after Transarterial Chemoembolization for Hepatocellular Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Study.
    Yang H; Seon J; Sung PS; Oh JS; Lee HL; Jang B; Chun HJ; Jang JW; Bae SH; Choi JY; Yoon SK
    J Vasc Interv Radiol; 2017 Nov; 28(11):1503-1511.e2. PubMed ID: 28941589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study.
    Lee S; Kim KM; Lee SJ; Lee KH; Lee DY; Kim MD; Kim DY; Kim SU; Won JY
    Acta Radiol; 2017 Feb; 58(2):131-139. PubMed ID: 27217418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transarterial chemoembolization for huge hepatocellular carcinoma with diameter over ten centimeters: a large cohort study.
    Xue T; Le F; Chen R; Xie X; Zhang L; Ge N; Chen Y; Wang Y; Zhang B; Ye S; Ren Z
    Med Oncol; 2015 Mar; 32(3):64. PubMed ID: 25682389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors influencing postembolization syndrome in patients with hepatocellular carcinoma undergoing first transcatheter arterial chemoembolization.
    He JJ; Yin XX; Wang T; Chen MY; Li XL; Yang XJ; Shao HY
    J Cancer Res Ther; 2021 Jul; 17(3):777-783. PubMed ID: 34269313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conventional versus Drug-Eluting Bead Transarterial Chemoembolization for Neuroendocrine Tumor Liver Metastases.
    Makary MS; Kapke J; Yildiz V; Pan X; Dowell JD
    J Vasc Interv Radiol; 2016 Sep; 27(9):1298-1304. PubMed ID: 27499157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does Preoperative Transarterial Chemoembolization for Hepatocellular Carcinoma Increase the Incidence of Hepatic Artery Thrombosis After Living-Donor Liver Transplant?
    Ince V; Ersan V; Karakas S; Kutluturk K; Karadag N; Kutlu R; Yilmaz S
    Exp Clin Transplant; 2017 Mar; 15(Suppl 2):21-24. PubMed ID: 28301994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interventional radiology in oncology: clinical management of patients undergoing transarterial chemoembolization for hepatic malignancies.
    Perez-Rojas E
    Clin J Oncol Nurs; 2012 Feb; 16(1):83-5. PubMed ID: 22297011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chemoembolization in hepatocellular carcinoma: multivariate analysis of survival prognostic factors after the first session].
    El Khaddari S; Gaudin JL; Abidi H; Picaud G; Rode A; Souquet JC
    Gastroenterol Clin Biol; 2002; 26(8-9):728-34. PubMed ID: 12434077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nausea and vomiting after transcatheter arterial chemoembolization for hepatocellular carcinoma: incidence and risk factor analysis.
    Wang SY; Zhu WH; Vargulick S; Lin SB; Meng ZQ
    Asian Pac J Cancer Prev; 2013; 14(10):5995-6000. PubMed ID: 24289614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-operative transarterial chemoembolization for resectable hepatocellular carcinoma adversely affects post-operative patient outcome.
    Kim IS; Lim YS; Lee HC; Suh DJ; Lee YJ; Lee SG
    Aliment Pharmacol Ther; 2008 Feb; 27(4):338-45. PubMed ID: 18047564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transarterial Chemoembolization with Small Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: Experience from a Cohort of 421 Patients at an Italian Center.
    Aliberti C; Carandina R; Lonardi S; Dadduzio V; Vitale A; Gringeri E; Zanus G; Cillo U
    J Vasc Interv Radiol; 2017 Nov; 28(11):1495-1502. PubMed ID: 28927662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.
    Dekervel J; van Malenstein H; Vandecaveye V; Nevens F; van Pelt J; Heye S; Laleman W; Van Steenbergen W; Vaninbroukx J; Verslype C; Maleux G
    J Vasc Interv Radiol; 2014 Feb; 25(2):248-55.e1. PubMed ID: 24295569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute pancreatitis induced by transarterial chemoembolization: a single-center experience of over 1500 cases.
    She WH; Chan AC; Cheung TT; Chok KSh; Chan SC; Poon RT; Lo CM
    Hepatobiliary Pancreat Dis Int; 2016 Feb; 15(1):93-8. PubMed ID: 26818549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Ischemic gastroduodenal ulcer as a complication of hepatic hepatocarcinoma transarterial chemoembolization].
    de Zárraga Mata C; Thomás Salom G; Maura Oliver ÁL
    Rev Gastroenterol Peru; 2019; 39(4):367-369. PubMed ID: 32097399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma responding to superselective transarterial chemoembolization: an issue of nodule dimension?
    Golfieri R; Renzulli M; Mosconi C; Forlani L; Giampalma E; Piscaglia F; Trevisani F; Bolondi L;
    J Vasc Interv Radiol; 2013 Apr; 24(4):509-17. PubMed ID: 23428355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.